The Valley Desk

NCT03631732 · Interventional trial

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Overall registry status Completed

Phase 3

Conditions HIV-1 Infection

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov